Revista do Hospital das Clínicas
-
Rev Hosp Clin Fac Med Sao Paulo · Mar 2001
Comparative StudyChemotherapy versus best supportive care in stage IV non-small cell lung cancer, non metastatic to the brain.
Stage IV non-small cell lung cancer is a fatal disease, with a median survival of 14 months. Systemic chemotherapy is the most common approach. However the impact in overall survival and quality of life still a controversy. ⋯ In patients with stage IV non-small cell lung cancer, non-metastatic to the brain, chemotherapy significantly increases survival compared with best supportive care.